Mar 20 |
2seventy bio appoints Eli Casdin and Charles Newton to its board of directors
|
Mar 20 |
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
|
Mar 16 |
Bristol Myers wins FDA AdCom backing for Abecma label expansion
|
Mar 15 |
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
|
Mar 7 |
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
|
Mar 6 |
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
|
Mar 5 |
2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript
|
Mar 5 |
2seventy bio GAAP EPS of -$1.11 misses by $0.06, revenue of $10.68M misses by $4.51M
|
Mar 5 |
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
|
Mar 5 |
Earnings Scheduled For March 5, 2024
|